How Much Does Semaglutide Cost Without Insurance in 2026?

The sticker price for semaglutide — roughly $1,350 a month — is what most people encounter first, and it stops a lot of people in their tracks. But that list price is almost never what patients actually pay in 2026.

Novo Nordisk's self-pay programs, negotiated telehealth pricing, and a major list price reduction coming in 2027 have fundamentally changed what semaglutide costs for people without insurance. This guide covers every pricing tier available today — and what is about to change.

The Numbers That Actually Matter

Here is the complete 2026 pricing picture for semaglutide, from list price to what you will realistically pay:

The gap between the list price and what self-pay patients actually pay through Novo Nordisk's own programs is significant. Most people paying cash in 2026 are paying $149–$349 per month — not $1,350.

Wegovy (Injection) Pricing Without Insurance

Wegovy's list price is approximately $1,350 per month. That is the price you would pay at a retail pharmacy without any savings program — and it is rarely what patients actually pay.

NovoCare Pharmacy (Novo Nordisk's direct program)

Novo Nordisk operates NovoCare Pharmacy as a direct-to-patient channel with significantly reduced cash pricing. As of April 2026:

• Starter doses (0.25 mg and 0.5 mg): $199/month — available for the first two monthly fills through June 30, 2026, then $349/month
• Maintenance doses (1 mg, 1.7 mg, 2.4 mg): $349/month
• Wegovy HD (7.2 mg, newly approved March 2026): Pricing not yet announced; expected availability April 2026 You can access NovoCare pricing directly at wegovy.com or through participating telehealth providers. The program is for cash-pay patients only — it cannot be combined with insurance.

GoodRx program

GoodRx has a partnership with Novo Nordisk for semaglutide. New patients can access Wegovy injection for $199/month for the first two fills, followed by $349/month for ongoing fills. This mirrors NovoCare pricing and uses the same NovoCare Pharmacy fulfillment infrastructure.

Telehealth platform pricing (injection)

Major FDA-approved telehealth providers have negotiated similar self-pay pricing. Across platforms like Hims/Hers, Ro, and Noom Med, cash-pay semaglutide injection pricing typically runs $199–$350/month. Some platforms bundle this into a flat monthly subscription that includes both the medication and clinical oversight; others charge the subscription and medication fee separately.

Key point: When comparing telehealth platform pricing, always confirm whether the quoted price includes the medication or is a subscription fee on top of the medication cost. "Starting at $149/month" sometimes means membership only, with medication billed separately.

Wegovy Pill Pricing Without Insurance

The Wegovy pill launched across the US in January 2026 — and its self-pay pricing is notably lower than the injection at every dose level.

NovoCare self-pay pricing (pill)

• Starter doses (1.5 mg and 4 mg): $149/month — through August 31, 2026, then $199/month for the 4 mg dose
• Higher/maintenance doses (9 mg and 25 mg): $299/month One important practical note: the Wegovy pill requires an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating or taking other medications. This timing window is the main lifestyle trade-off relative to the injection.

Why the pill is cheaper

The lower self-pay pricing for the pill reflects Novo Nordisk's strategy to drive oral semaglutide adoption and compete directly with the newer oral GLP-1 options (particularly Eli Lilly's Foundayo, approved April 2026, which starts at $149/month with no food restrictions). For patients who are needle-averse or prefer a daily routine, the pill now offers both a lower cash-pay entry price and a lower maintenance price than the injection.

Ozempic Pricing Without Insurance

Ozempic is FDA-approved for type 2 diabetes, not weight loss. It is sometimes prescribed off-label for weight management. Its list price is approximately $1,027 per month.

NovoCare cash-pay pricing (Ozempic)

• New patients (0.25 mg and 0.5 mg intro doses): $199/month for the first two fills
• Existing patients (0.25 mg, 0.5 mg, 1 mg doses): $349/month
• Existing patients (2 mg dose): $499/month Important context: because Ozempic is a diabetes medication, insurance coverage works differently than for Wegovy. Patients who have a type 2 diabetes diagnosis may find Ozempic covered by plans that explicitly exclude weight loss drugs. Conversely, patients without diabetes who want semaglutide for weight loss will generally find Wegovy is the more appropriate and more insurance-accessible path.

What Is Changing in 2027

This is the most significant development in semaglutide pricing in years: Novo Nordisk has announced that the list price for Wegovy, Ozempic, and Rybelsus will be reduced to approximately $675 per month effective January 1, 2027. That represents roughly a 50% reduction from today's list price.

What this means practically:

• Patients on high-deductible plans who currently pay coinsurance based on the list price will see a meaningful reduction in their cost-sharing
• Patients whose plans cover Wegovy at a percentage of list price (rather than a fixed copay) will pay less
• The change does not affect NovoCare Pharmacy direct cash-pay pricing, which operates independently of the list price The 2027 reduction is partly a response to government drug pricing negotiations. Wegovy was among the 15 medications selected for Medicare price negotiations in 2025 under the Inflation Reduction Act, with negotiated prices set to take effect in 2027.

If you are currently on semaglutide or planning to start, this is worth factoring into your long-term cost calculations — particularly if you are weighing a high-deductible plan or a coinsurance structure that would benefit from the lower list price.

Wegovy HD: The New High-Dose Option

In March 2026, the FDA approved Wegovy HD — a 7.2 mg weekly injectable formulation of semaglutide, the highest dose approved for any semaglutide weight loss product. It is intended for patients who have tolerated the 2.4 mg Wegovy dose for at least four weeks and need additional weight loss.

Pricing for Wegovy HD had not been finalized at the time this article was published. It is expected to be available through NovoCare Pharmacy and participating telehealth providers in April 2026. We will update this section as pricing is confirmed.

Insurance Coverage: The Complicated Picture

Even though this article focuses on costs without insurance, understanding the insurance landscape shapes the decision about whether to pursue coverage.

Commercial insurance

Only around 20–25% of commercial insurance plans currently cover GLP-1 weight loss medications. Many plans explicitly exclude them, treating obesity as outside their covered benefits. Some major insurers — including certain Blue Cross Blue Shield plans — have actually tightened GLP-1 coverage in 2026, removing or restricting benefits that were previously available.

Even when a plan does cover Wegovy, prior authorization is almost always required. The insurer must determine that your BMI, health history, and prior treatment attempts meet its criteria before approving coverage.

If your plan covers Wegovy and you have commercial insurance, a Novo Nordisk savings card can reduce your out-of-pocket cost to as little as $25 per month.

Medicare

Medicare Part D does not cover semaglutide for weight loss as a standalone indication. However, Medicare Part D does cover Wegovy for adults who have both cardiovascular disease and obesity or overweight — the cardiovascular risk reduction indication that the FDA approved in March 2024. If you have a qualifying cardiovascular condition (history of heart attack, stroke, or established cardiovascular disease), coverage may be available. Confirm with your specific plan.

Medicaid

Medicaid coverage varies significantly by state. A small number of states cover GLP-1 weight loss medications; most do not. Contact your state Medicaid program directly for current coverage information.

HSA and FSA

Both brand-name semaglutide (Wegovy, Ozempic) and compounded semaglutide are generally eligible for payment through HSA or FSA accounts when prescribed for a qualifying medical condition. This does not reduce the price, but it does mean you are paying with pre-tax dollars — a meaningful 22–37% effective discount depending on your tax bracket.

How to Access the Lowest Cash-Pay Price

If you are paying out of pocket, here is the sequence of steps to access the best available pricing:

1. Go through a participating telehealth provider or NovoCare directly. Retail pharmacies (CVS, Walgreens, Rite Aid) dispense Wegovy at or near list price unless you have insurance. The self-pay pricing through NovoCare Pharmacy or participating telehealth platforms is dramatically lower and requires a valid prescription.

2. Start with the introductory rate. New patients who have not previously filled Wegovy or Ozempic can access the $199/month injection or $149/month pill introductory pricing for the first two fills (through June 30, 2026 for the injection). If you have previously used either medication, the standard maintenance pricing applies from the start.

3. Compare total monthly cost across platforms. The NovoCare self-pay pricing is available through multiple channels — Wegovy.com directly, GoodRx, and participating telehealth providers. The medication price is the same across channels; what differs is the platform subscription fee and the level of clinical oversight. Compare the all-in monthly cost (subscription + medication) when evaluating telehealth providers.

4. Use an HSA or FSA card. Even at $299/month (Wegovy pill maintenance price), paying through an HSA or FSA effectively reduces that cost by your marginal tax rate. On a $299 monthly medication bill, that is a real dollar savings of $66–$110 per month for most earners.

5. Know when the introductory offer expires and plan accordingly. The Wegovy injection introductory rate ($199/month) runs through June 30, 2026. After that, starter-dose pricing increases to $349/month under current terms. If you are starting semaglutide soon, the introductory window is meaningful.

Month-by-Month Cost Estimate: What to Budget

Most patients take 5–7 months to reach their maintenance dose. Here is a realistic cash-pay budget for a patient starting on Wegovy injection today through NovoCare, paying the self-pay rate:

Total through month 5 (injection): ~$1,445

For the Wegovy pill, the same titration at NovoCare self-pay rates:

Total through month 5 (pill): ~$1,094

These are medication-only costs through NovoCare Pharmacy. If you access the medication through a telehealth platform, add the platform's monthly subscription fee (typically $59–$199/month depending on the provider).

Common Questions

Is there a generic semaglutide available?

No. There is no FDA-approved generic version of Wegovy or Ozempic. The semaglutide patent held by Novo Nordisk does not expire in the US for several years. Compounded semaglutide is not a generic — it is a different product manufactured by compounding pharmacies and is not FDA-approved.

This site covers FDA-approved brand-name medications only. For a detailed explanation of the difference between brand-name and compounded semaglutide, see our article on compounded vs. brand-name semaglutide.

Can I buy semaglutide from Canada or another country to save money?

Semaglutide is available at lower prices in other countries — the same brand-name Wegovy costs roughly $300–$500/month in Canada and the UK under those countries' pricing frameworks. However, importing prescription medications for personal use is technically illegal under US federal law, even in small quantities, and the FDA does not guarantee the safety or authenticity of medications purchased from foreign pharmacies. We do not recommend this approach.

Does the cost of semaglutide go down over time?

Effective January 1, 2027, Novo Nordisk will reduce the list price of Wegovy to approximately $675/month. This will directly reduce cost-sharing for patients on plans with coinsurance (percentage-based cost sharing). NovoCare direct pricing is not tied to the list price and may or may not change at the same time — Novo Nordisk has not confirmed 2027 NovoCare rates.

What if I can't afford semaglutide at all?

Novo Nordisk operates a patient assistance program called NovoCare for patients who are uninsured or underinsured and meet income eligibility requirements. Qualifying patients may receive Wegovy at no cost or significantly reduced cost. Eligibility is income-based and requires documentation. Apply at novocare.com.

What does semaglutide cost at a retail pharmacy without any program?

At a retail pharmacy counter without insurance or a savings program, Wegovy is priced at the list price of approximately $1,350/month. This is the price to avoid. Whether you access semaglutide through NovoCare directly, GoodRx, or a telehealth platform, you should never be paying the retail list price as a cash-pay patient in 2026.

The Bottom Line

The $1,350 list price for Wegovy is real — but it is not what most people actually pay in 2026. The realistic cash-pay range for brand-name semaglutide through legitimate programs is:

• $149/month to start on the Wegovy pill (introductory dose, NovoCare, through August 2026)
• $199/month to start on the Wegovy injection (introductory dose, NovoCare, through June 2026)
• $299–$349/month for ongoing maintenance doses These prices are available directly through NovoCare Pharmacy, through GoodRx's program, and through the major FDA-approved telehealth providers — no insurance required, no prior authorization, no waiting.

The platform you choose affects more than just price — it determines your clinical oversight, follow-up quality, and access to dose adjustments. Our provider comparison page breaks down the true all-in monthly cost across every major FDA-approved telehealth platform, so you can see exactly what you will pay from day one.